Key result
Elevated cTnI linked to ~8-fold higher risk of unfavorable short-term outcomes in acute ischemic stroke.
Why the study?
The study was conducted to evaluate whether elevated cardiac troponin I acts as an indicator of unfavorable functional outcomes in ischemic stroke.
Does elevated baseline cardiac troponin I predict unfavorable functional outcomes and mortality in patients with acute ischemic stroke?
Cohort (n=100)
No
Does elevated baseline cardiac troponin I predict unfavorable functional outcomes and mortality in patients with acute ischemic stroke?
Elevated baseline cardiac troponin I is a strong, independent predictor of 90-day mortality and unfavorable functional outcomes in patients with acute ischemic stroke.
May aid prognostic stratification in acute ischemic stroke; hypothesis-generating and should not yet change practice.
OBJECTIVE: To assess if elevated cardiac troponin I (cTnI) serves as a sign of unfavorable functional outcomes in ischemic stroke. METHODS: In this single-center prospective cohort study, 100 consecutive patients admitted with acute ischemic stroke (normal troponin I group n = 52, raised troponin I group n = 48) were included. Hospital mortality was documented in both groups; the remaining patients were followed up to 90 days. Then two groups were compared in terms of unfavorable short-term outcomes (Modified Rankin Scale > 3) and mortality. Multivariate logistic regression was conducted to determine the predictive value of elevated cTnI. The Kaplan-Meier curve was drawn and compared to determine the difference in survival between the two groups. To find out the most probable cut-off level for an unfavorable outcome, a receiver operating characteristic (ROC) analysis was conducted. RESULT: A higher frequency of coronary artery disease (p=0.030), higher National Institutes of Health Stroke Scale (NIHSS) (p=0.008) score, and lower Glasgow Coma Scale (GCS) (p=0.002) was observed in raised troponin I group. Even after the exclusion of confounding elevated troponin I was found to be an independent predictor of unfavorable outcomes (adjusted odds ratio, OR 8.25 {95% confidence interval, CI: 2.65-25.75}; p<0.001). The patients with raised troponin I had a significantly lower rate of survival after 90 days (p=0.022). The elevated troponin I was observed to have a significantly high accuracy (p<0.001; area under curve, AUC: 0.768 {moderate accuracy}, 95% CI: 0 .676 to 0.861) in predicting unfavorable outcomes. CONCLUSION: Elevated cTnI is independently associated with unfavorable short-term outcomes. It is also associated with a lower rate of survival.
No takes yet. Share an insight, caveat, or question.
Esteak et al. (2023) conducted a cohort in Acute ischemic stroke (n=100). Elevated cardiac troponin I vs. Normal troponin I was evaluated on Unfavorable short-term outcome (Modified Rankin Scale > 3) (OR 8.25, 95% CI 2.65-25.75, p=<0.001). Elevated cardiac troponin I was independently associated with an increased risk of unfavorable short-term outcomes (OR 8.25) and lower 90-day survival in patients with acute ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: